C4 Therapeutics Inc

NASDAQ:CCCC

2.23

+0.24 (+12.06%)

7:59:25 PM EDT: $2.25 +0.02 (+0.90%)

Market Cap (Intraday)	177.44M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$5.24 Million
Adjusted EPS	-$0.40

See more estimates

10-Day MA	$1.79
50-Day MA	$1.53
200-Day MA	$3.21

See more pivots

C4 Therapeutics Inc Stock, NASDAQ:CCCC

490 Arsenal Way, Suite 120, Watertown, Massachusetts 02472

United States of America

Phone: +1.617.231.0700

Number of Employees: 110

http://www.c4therapeutics.com

Description

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.